![](/img/cover-not-exists.png)
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
Lonial, Sagar, Dimopoulos, Meletios, Weisel, Katja, White, Darrell, Moreau, Philippe, Mateos, Maria-Victoria, San Miguel, Jesus, Anderson, Kenneth, Shpilberg, Ofer, Grosicki, Sebastian, Spicka, Ivan,Volume:
18
Language:
english
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2018.07.155
Date:
September, 2018
File:
PDF, 66 KB
english, 2018